Effectiveness of Laying-on-of-hands for Sickle Cell Disease

NCT01518218 | Completed Phase 2 DMC

• 1 other identifier: MOA-002
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate the effectiveness of 1-year administration of laying-on-of-hands on the morbidity and mortality of patients with sickle cell disease in Africa.

Conditions

Sickle Cell Disease; Pain Crisis Recurrent; Anemia; Infection; Death

Keywords

Sickle cell disease; laying-on-of-hands; morbidity; mortality

Outcome Measures

Primary Outcomes (1)

• disease-related episodes and mortality

  3 years and 9 months

Secondary Outcomes (1)

• blood data

  1 year

Study Arms (2)

laying-on-of-hands

EXPERIMENTAL

Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.

Behavioral: laying-on-of-hands

control group

NO INTERVENTION

Patients of this arm did not receive any alternatives other than conventional treatment.

Interventions

laying-on-of-hands BEHAVIORAL

The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.

Also known as: Okada Purifying Therapy, biofield therapy

laying-on-of-hands

Eligibility Criteria

• Age: 3 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• patients with symptoms associated with sickle cell disease
• those able to receive laying-on-of-hands every weekday for 1 year
• those able to receive conventional medical treatment whenever necessary
• those able to receive blood test at the beginning, after 6 month and after 1 year

You may not qualify if:

• those who wish to use other complementary and alternative therapies along with laying-on-of-hands

Sponsors & Collaborators

• MOA Health Science Foundation: lead

Study Sites (1)

The national medical center for sickle cell disease

Kinshasa, Democratic Republic of the Congo

Location

Related Publications (1)

• Minga TM, Koto FK, Egboki H, Suzuki K. Effectiveness of biofield therapy for individuals with sickle cell disease in Africa. Altern Ther Health Med. 2014 Jan-Feb;20(1):20-6.

  PMID: 24445353 DERIVED

Related Links

• MOA International Corporation

MeSH Terms

Conditions

Anemia, Sickle Cell; Anemia; Infections; Death

Interventions

Therapeutic Touch

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Mind-Body Therapies; Complementary Therapies; Therapeutics; Spiritual Therapies

Study Officials

• Kodondi K Koto, MD, PhD

  The Institute of Scientific Research for Health, Kinshasa

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: president

Study Record Dates

• First Submitted: January 21, 2012
• First Posted: January 25, 2012
• Study Start: March 1, 2006
• Primary Completion: March 1, 2007
• Study Completion: December 1, 2009
• Last Updated: April 13, 2015

Record last verified: 2012-01

Locations

DE (1)